These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 27338952)

  • 1. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
    Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
    Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
    Mendoza P; Gruell H; Nogueira L; Pai JA; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Lorenzi JCC; Cohen YZ; Wyen C; Kümmerle T; Karagounis T; Lu CL; Handl L; Unson-O'Brien C; Patel R; Ruping C; Schlotz M; Witmer-Pack M; Shimeliovich I; Kremer G; Thomas E; Seaton KE; Horowitz J; West AP; Bjorkman PJ; Tomaras GD; Gulick RM; Pfeifer N; Fätkenheuer G; Seaman MS; Klein F; Caskey M; Nussenzweig MC
    Nature; 2018 Sep; 561(7724):479-484. PubMed ID: 30258136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination anti-HIV antibodies provide sustained virological suppression.
    Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
    Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.
    Cohen YZ; Lorenzi JCC; Krassnig L; Barton JP; Burke L; Pai J; Lu CL; Mendoza P; Oliveira TY; Sleckman C; Millard K; Butler AL; Dizon JP; Belblidia SA; Witmer-Pack M; Shimeliovich I; Gulick RM; Seaman MS; Jankovic M; Caskey M; Nussenzweig MC
    J Exp Med; 2018 Sep; 215(9):2311-2324. PubMed ID: 30072495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
    Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between intact HIV-1 proviruses in circulating CD4
    Lu CL; Pai JA; Nogueira L; Mendoza P; Gruell H; Oliveira TY; Barton J; Lorenzi JCC; Cohen YZ; Cohn LB; Klein F; Caskey M; Nussenzweig MC; Jankovic M
    Proc Natl Acad Sci U S A; 2018 Nov; 115(48):E11341-E11348. PubMed ID: 30420517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
    Bar KJ; Sneller MC; Harrison LJ; Justement JS; Overton ET; Petrone ME; Salantes DB; Seamon CA; Scheinfeld B; Kwan RW; Learn GH; Proschan MA; Kreider EF; Blazkova J; Bardsley M; Refsland EW; Messer M; Clarridge KE; Tustin NB; Madden PJ; Oden K; O'Dell SJ; Jarocki B; Shiakolas AR; Tressler RL; Doria-Rose NA; Bailer RT; Ledgerwood JE; Capparelli EV; Lynch RM; Graham BS; Moir S; Koup RA; Mascola JR; Hoxie JA; Fauci AS; Tebas P; Chun TW
    N Engl J Med; 2016 Nov; 375(21):2037-2050. PubMed ID: 27959728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.
    Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS
    Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.
    Shingai M; Nishimura Y; Klein F; Mouquet H; Donau OK; Plishka R; Buckler-White A; Seaman M; Piatak M; Lifson JD; Dimitrov DS; Nussenzweig MC; Martin MA
    Nature; 2013 Nov; 503(7475):277-80. PubMed ID: 24172896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.
    Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir.
    Yu WH; Su D; Torabi J; Fennessey CM; Shiakolas A; Lynch R; Chun TW; Doria-Rose N; Alter G; Seaman MS; Keele BF; Lauffenburger DA; Julg B
    JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
    Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
    Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
    Cohen YZ; Butler AL; Millard K; Witmer-Pack M; Levin R; Unson-O'Brien C; Patel R; Shimeliovich I; Lorenzi JCC; Horowitz J; Walsh SR; Lin S; Weiner JA; Tse A; Sato A; Bennett C; Mayer B; Seaton KE; Yates NL; Baden LR; deCamp AC; Ackerman ME; Seaman MS; Tomaras GD; Nussenzweig MC; Caskey M
    PLoS One; 2019; 14(8):e0219142. PubMed ID: 31393868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
    Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.
    Cale EM; Bai H; Bose M; Messina MA; Colby DJ; Sanders-Buell E; Dearlove B; Li Y; Engeman E; Silas D; O'Sullivan AM; Mann B; Pinyakorn S; Intasan J; Benjapornpong K; Sacdalan C; Kroon E; Phanuphak N; Gramzinski R; Vasan S; Robb ML; Michael NL; Lynch RM; Bailer RT; Pagliuzza A; Chomont N; Pegu A; Doria-Rose NA; Trautmann L; Crowell TA; Mascola JR; Ananworanich J; Tovanabutra S; Rolland M;
    J Clin Invest; 2020 Jun; 130(6):3299-3304. PubMed ID: 32182219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
    Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
    Caskey M; Schoofs T; Gruell H; Settler A; Karagounis T; Kreider EF; Murrell B; Pfeifer N; Nogueira L; Oliveira TY; Learn GH; Cohen YZ; Lehmann C; Gillor D; Shimeliovich I; Unson-O'Brien C; Weiland D; Robles A; Kümmerle T; Wyen C; Levin R; Witmer-Pack M; Eren K; Ignacio C; Kiss S; West AP; Mouquet H; Zingman BS; Gulick RM; Keler T; Bjorkman PJ; Seaman MS; Hahn BH; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC; Klein F
    Nat Med; 2017 Feb; 23(2):185-191. PubMed ID: 28092665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.